Physician

Psychiatry

Dr. Douglas E. Feltner, MD

Dr. Douglas E. Feltner works in the field of Psychiatry. He researched medicine at University of Michigan Medical School. Douglas Feltner is a published physician. He has 39 publications published. The most current publication "Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice."

Publications

Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study.
Evaluation of the subjective and reinforcing effects of diphenhydramine, levetiracetam, and valproic acid.
Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needs.
Clinical evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A): a new instrument to assess the onset of symptomatic improvement in generalized anxiety disorder.
Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.
Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing.
Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study.
A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder.
Pregabalin in generalized anxiety disorder: a placebo-controlled trial.
Study Site Experiences and Attitudes Toward Prospective Assessments of Suicidal Ideation and Behavior in Clinical Trials: Results of an Internet-based Survey.
Progress in the treatment of tardive dyskinesia: theory and practice.
Chemotactic factor binding by metastatic tumour cells: evidence for a formyl-peptide receptor on a non-myelogenous cell.
Covalent affinity labeling, detergent solubilization, and fluid-phase characterization of the rabbit neutrophil formyl peptide chemotaxis receptor.
Phagocytic cell-derived inflammatory mediators and lung disease.
Characterization of the plasma membrane bound GTPase from rabbit neutrophils. I. Evidence for an Ni-like protein coupled to the formyl peptide, C5a, and leukotriene B4...
Formyl peptide chemotaxis receptors on the rat neutrophil: experimental evidence for negative cooperativity.
Regulation of formyl peptide receptor binding to rabbit neutrophil plasma membranes. Use of monovalent cations, guanine nucleotides, and bacterial toxins to discrimina...
Expression of class I histocompatibility antigens in neuroectodermal tumors is independent of the expression of a transfected neuroblastoma myc gene.
Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice.
The use of a clinical utility index to compare insomnia compounds: a quantitative basis for benefit-risk assessment.
A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression.
Long-term efficacy of pregabalin in generalized anxiety disorder.
Development and evaluation of the Daily Assessment of Symptoms - Anxiety (DAS-A) scale to evaluate onset of symptom relief in patients with generalized anxiety disorder.
The patient experience of depression and remission: focus group results.
Comments on "Presidential address: advocacy as leadership".
Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission.
Evaluation of the abuse potential of pagoclone, a partial GABAA agonist.
A statistical approach for classifying change in cognitive function in individuals following pharmacologic challenge: an example with alprazolam.
How modeling and simulation have enhanced decision making in new drug development.
A method for determining the magnitude of change across different cognitive functions in clinical trials: the effects of acute administration of two different doses al...
Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder.
Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit.
Development of a patient-reported assessment to identify placebo responders in a generalized anxiety disorder trial.
Incorporating the assessment of abuse liability into the drug discovery and development process.
Psychometric evaluation of a visual analog scale for the assessment of anxiety.
Pharmacodynamic differentiation of lorazepam sleepiness and dizziness using an ordered categorical measure.
Identifying HAM-A cutoffs for mild, moderate, and severe generalized anxiety disorder.
Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study.

Schools

University of Mi Med Sch
Clinical Center At The Nih
Geo Washington University Hospital

Doctors Specialties

Psychiatry

Accepted Insurances

Education

National Institutes of Health Clinical Center
George Washington University
University of Michigan Medical School

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Mark Lyubkin, MD This Doctor is OpenDoctor Recommended.
	Dr. Mark A. Demitrack, MD
	Dr. John F. Greden, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Shabnum H. Sheikh, MD This Doctor is OpenDoctor Recommended.
	Dr. Julia A. Hardy, MD This Doctor is OpenDoctor Recommended.
	Dr. James B. Miner, MD
	Dr. Marie Thompson, MD
	Dr. Laura K. Reese, MD
	Dr. Sanjay Jasuja, MD
	Dr. Zara Masood, MD
	Dr. Ryan M. Silwanowicz, MD This Doctor is OpenDoctor Recommended.